Many pathogens such as HIV, SARS-CoV-2, or those linked to influenza or cholera infect the host through mucosal surfaces and thus are thought to require both systemic and mucosal immune responses for effective management and protection. Read More
Clade C subtype-specific HIV-1 infections are responsible for over 48% of global HIV-1 burden. Aiming to develop a vaccine that provides heterologous protection against HIV, a research group led by investigators from the Emory Vaccine Center at Emory University recently reported a novel clade C HIV-1 vaccine. Read More
Beijing Erai Therapeutics has identified aminoheteroaryl compounds acting as mitochondrial brown fat uncoupling protein 1 (UCP1) activators reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH), diabetes and obesity. Read More
Shanghai Hengrui Pharmaceutical and Jiangsu Hengrui Medicine have described cyclohexadiimide derivatives reported to be useful for the treatment of cancer and neurological disorders. Read More
Yale University has presented new 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection. Read More
Helios-Huaming BioPharma has synthesized new substituted salicylamide compounds acting as protein-arginine deiminase type-4 (PADI4) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis and ischemia-reperfusion injury, among other disorders. Read More
It has been previously demonstrated that MYCN amplification frequently occurs in high-risk neuroblastoma (NB), and it is correlated with an undifferentiated phenotype and poor prognosis. Read More
Data from preclinical studies conducted to examine the activities of the novel estrogen receptor beta (ERbeta) agonist EGX-358, previously under study for the treatment of hot flushes at Estrigenix Therapeutics, for the potential treatment of Alzheimer's disease (AD) were presented at the recent Alzheimer's Association International Conference. Read More
The FDA has cleared Jubilant Therapeutics' IND application for JBI-778, an oral, brain-penetrant and selective protein arginine methyl transferase 5 (PRMT5) inhibitor, for the treatment of solid tumors with brain metastases and primary brain tumors, including high-grade glioma. Read More
Lynk Pharmaceuticals' LNK-01004 has been cleared by China's National Medical Products Administration (NMPA) for clinical trials in the treatment of atopic dermatitis. Read More
A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens up a previously unexplored field of research in the molecular and cellular mechanisms triggered after death, an area of potential significance, since it covers different biological processes with multiple applications. Read More
